The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Abstract
Purpose: To compare pemetrexed/carboplatin with a standard regimen as first-line therapy in advanced non–small-cell lung cancer NSCLC. Patients and Methods: Patients with stage IIIB or IV NSCLC and performance status of 0 to 2 were randomly assigned to receive pemetrexed 500 mg/m 2 plus carboplatin area under the curve (AUC) = 5 (Calvert's formula) on day 1 or gemcitabine 1,000 mg/m 2 on days 1 and 8 plus carboplatin AUC = 5 on day 1 every 3 weeks for up to four cycles. The primary end point was health-related quality of life (HRQoL) defined as global quality of life, nausea/vomiting, dyspnea, and fatigue reported on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and the lung cancer–specific module LC13 during the first 20 weeks. Secondary end points were overall survival and toxicity. Results: Four hundred thirty-six eligible patients were enrolled from April 2005 to July 2006. Patients who completed the baseline questionnaire were analyzed for HRQoL (n = 427), and those who received ≥ one cycle of chemotherapy were analyzed for toxicity (n = 423). Compliance of HRQoL questionnaires was 87%. There were no significant differences for the primary HRQoL end points or in overall survival between the two treatment arms (pemetrexed/carboplatin, 7.3 months; gemcitabine/carboplatin, 7.0 months; P = .63). The patients who received gemcitabine/carboplatin had more grade 3 to 4 hematologic toxicity than patients who received pemetrexed/carboplatin, including leukopenia (46% v 23%, respectively; P < .001), neutropenia (51% v 40%, respectively; P = .024), and thrombocytopenia (56% v 24%, respectively; P < .001). More patients on the gemcitabine/carboplatin arm received transfusions of RBCs and platelets, whereas the frequencies of neutropenic infections and thrombocytopenic bleedings were similar on both arms. Conclusion: Pemetrexed/carboplatin provides similar HRQoL and survival when compared with gemcitabine/carboplatin with less hematologic toxicity and less need for supportive care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Self-citationComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,018
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 885
Self-citationElderly Lung Cancer Vinorelbine Italian Study Group (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.66 · Cited by 869
Quality of Life: The Assessment, Analysis and Interpretation of Patient‐Reported Outcomes
Fayers, P. M., & Machin, D. (2007) · doi:10.1002/9780470024522 · Cited by 865
Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612
Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.025 · Cited by 555
Langer, C. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.173 · Cited by 502
Socinski, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1335 · Cited by 379
Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.109 · Cited by 364
Ceppi, P., Volante, M., Saviozzi, S., Rapa, I., Novello, S., Cambieri, A., Lo Iacono, M., Cappia, S., Papotti, M., & Scagliotti, G. V. (2006) · Cancer · doi:10.1002/cncr.22208 · Cited by 363
Anderson, H., Hopwood, P., Stephens, R. J., Thatcher, N., Cottier, B., Nicholson, M., Milroy, R., Maughan, T. S., Falk, S. J., Bond, M. G., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1307 · Cited by 338
Finkelstein, D. M., Ettinger, D. S., & Ruckdeschel, J. C. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.5.702 · Cited by 325
Smith, I. E., O’Brien, M. E. R., Talbot, D. C., Nicolson, M. C., Mansi, J. L., Hickish, T. F., Norton, A., & Ashley, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1336 · Cited by 308
Bezjak, A., Tu, D., Seymour, L., Clark, G., Trajkovic, A., Zukin, M., Ayoub, J., Lago, S., de Albuquerque Ribeiro, R., Gerogianni, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8073 · Cited by 296
Osoba, D., Bezjak, A., Brundage, M., Zee, B., Tu, D., & Pater, J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.017 · Cited by 288
Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R. M., Vansteenkiste, J., Thatcher, N., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.10.014 · Cited by 277
Park, J. O., Kim, S.-W., Ahn, J. S., Suh, C., Lee, J. S., Jang, J. S., Cho, E. K., Yang, S. H., Choi, J.-H., Heo, D. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8134 · Cited by 180
Dancey, J. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2003.09.001 · Cited by 164
for the Norwegian Lung Cancer Study Group, von Plessen, C., Bergman, B., Andresen, O., Bremnes, R. M., Sundstrøm, S., Gilleryd, M., Stephens, R., Vilsvik, J., Aasebø, U., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603383 · Cited by 158
Self-citationManegold, C., Gatzemeier, U., von Pawel, J., Pirker, R., Malayeri, R., Blatter, J., & Krejcy, K. (2000) · Annals of Oncology · doi:10.1023/a:1008336931378 · Cited by 154
Belani, C. P., & Fossella, F. V. (2005) · Cancer · doi:10.1002/cncr.21495 · Cited by 150
Wakelee, H. A., Wang, W. T., Schiller, J. H., Langer, C. J., Sandler, A. B., Belani, C. P., & Johnson, D. H. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31609-9 · Cited by 146
Scagliotti, G. V., Kortsik, C., Dark, G. G., Price, A., Manegold, C., Rosell, R., O'Brien, M. E. R., Peterson, P. M., Castellano, D., Selvaggi, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.690.11.2 · Cited by 146
Shepherd, F. A., Dancey, J. E., Arnold, A., Neville, A., Rusthoven, J. J., Johnson, R. D., Fisher, B., & Eisenhauer, E. A. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3<595::aid-cncr1359>3.0.co;2-d · Cited by 144
Helsing, M., Bergman, B., Thaning, L., & Hero, U. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10122-8 · Cited by 132
Ohe, Y., Ichinose, Y., Nakagawa, K., Tamura, T., Kubota, K., Yamamoto, N., Adachi, S., Nambu, Y., Fujimoto, T., Nishiwaki, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5143 · Cited by 121
Jatoi, A., Hillman, S. L., Stella, P. J., Green, E., Adjei, A. A., Nair, S., Perez, E. A., Amin, B., Schild, S. E., Castillo, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7465 · Cited by 116
Peterson, P. M., Park, K., Fossella, F. V., Gatzemeier, U., John, W. J., & Scagliotti, G. V. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000284677.33344.62 · Cited by 110
Jiang, J., Liang, X., Zhou, X., Huang, R., & Chu, Z. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.03.014 · Cited by 98
Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
Ciuleanu, T., Brodowicz, T., Belani, C. P., Kim, J., Krzakowski, M. J., Laack, E., Wu, Y.-L. L. C., Peterson, P. M., Adachi, S., & Zielinski, C. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8011 · Cited by 98
Macquart-Moulin, G., Viens, P., Bouscary, M.-L., Genre, D., Resbeut, M., Gravis, G., Camerlo, J., Maraninchi, D., & Moatti, J. P. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.610 · Cited by 92
Zinner, R., Fossella, F. V., Gladish, G. W., Glisson, B. S., Blumenschein, G. R., Papadimitrakopoulou, V. A., Pisters, K. M. W., Kim, E. S., Oh, Y. W., Peeples, B. O., et al. (2005) · Cancer · doi:10.1002/cncr.21480 · Cited by 90
for the Norwegian Lung Cancer Study Group, Helbekkmo, N., Sundstrøm, S. H., Aasebø, U., Brunsvig, P. F., von Plessen, C., Hjelde, H. H., Garpestad, O. K., Bailey, A., & Bremnes, R. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603869 · Cited by 75
Self-citationScagliotti, G. V. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-9009 · Cited by 62
Is cancer treatment toxicity accurately reported?
Parliament, M. B., Danjoux, C. E., & Clayton, T. C. (1985) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(85)90195-6 · Cited by 28
Cited by
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Ettinger, D. S., Akerley, W., Borghaei, H., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K. P., Govindan, R., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0130 · Cited by 349
The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J.-C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8126 · Cited by 300
Metadata
- Authors
- Grønberg, B. H., Bremnes, R. M., Fløtten, Ø., Amundsen, T., Brunsvig, P. F., Hjelde, H. H., Kaasa, S., von Plessen, C., Stornes, F., Tollåli, T., Wammer, F., Aasebø, U., & Sundstrøm, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-01
- Volume
- 27
- Issue
- 19
- Pages
- 3217-3224
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106664438
- Cited by
- 288
- References
- 43
- FWCI
- 23.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.